Please try another search
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Jinn-Der Chang | - | 2014 | Independent Director |
Ko-Chung Lin | - | 2017 | Founder, CEO, Chief Strategy Officer & Director |
Yen Ching Hwang | - | 2021 | Director |
Ching-Leou Teng | - | 2012 | Chairman & Chief Pharmaceutical Officer |
Norio Komatsu | - | 2021 | Chairperson of Japan |
Chan-Kou Hwang | - | 2015 | President, GM & Director |
Patrick Y. Yang | 76 | 2014 | Independent Director |
Shen You Gong | - | 2021 | Director |
Jien-Heh Tien | - | 2018 | Independent Director |
Ben-Yuan Chen | - | 2006 | Director |
Shen Yi Li | - | 2021 | Director |
Chien-Hsin Lai | - | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review